全球抗癌藥物市場規模（按產品、應用、地區、範圍和預測）

抗癌藥物的市場規模及預測

抗腫瘤藥物市場規模預計在2023 年達到1257.1 億美元，預計在2024 年至2030 年期間將以7.1% 的複合年增長率增長，到2030 年將達到2854.9 億美元。達到美國10萬美元。

抗腫瘤藥物的全球市場推動因素

抗癌藥物市場的市場推動因素會受到多種因素的影響。

癌症發生率不斷上升：

抗癌藥物市場受到全球癌症發生率上升的顯著影響。由於人口老化、生活方式改變和環境因素導致的癌症發生率上升，對有效的癌症治療方法（包括抗腫瘤藥物）的需求也隨之增加。

癌症研究的進展：

隨著癌症分子生物學原因的闡明和個人化治療方法的發展，抗癌藥物的市場正在不斷擴大。與傳統化療相比，標靶療法副作用更小、治療更有針對性，因此其使用率更高，市場也越來越大。

技術進步：

隨著藥物傳遞系統的進步，包括脂質體、奈米顆粒和定製藥物傳遞平台，抗癌藥物的安全性和有效性得到了提高。這些技術發展透過改善患者體驗和治療結果來支持市場發展。

增加醫療支出：

醫療保健支出的增加推動了包括抗癌藥物在內的尖端癌症治療方法的採用，尤其是在發展中國家。患者知識的提高、保險覆蓋範圍的擴大和政府的措施都有助於使這些治療更容易獲得。

管道開發：

市場擴張的動力來自於大量針對各種癌症的創新腫瘤藥物。製藥公司和學術機構正在透過開發和測試新藥物和治療方案不斷增加治療選擇的範圍。

改善治療效果：

由於個人化醫療的趨勢，針對性抗癌藥物的需求很高，在個人化醫療中，治療計畫會考慮到患者的遺傳和腫瘤生物標記等特徵。隨著個人化技術改善治療效果並減少副作用，市場正在擴大。

監理支援：

旨在加速藥物開發的監管計劃促進了腫瘤藥物的市場開發。此類措施的例子包括加快審批流程和孤兒藥分類激勵措施。良好的監管框架將促進新藥的快速商業化，並有助於擴大市場。

老化世界：

由於人口老化，對抗癌藥物的需求不斷增加，這導致癌症發生率不斷上升，尤其是在工業化國家。老化趨勢導致癌症風險增高，推高了治療費用，擴大了市場規模。

新興經濟體：

拉丁美洲、非洲和亞太地區的新興國家腫瘤藥物市場具有巨大的成長空間。在這些地區，由於可支配收入增加、城市化快速發展和醫療保健基礎設施改善等因素，晚期癌症治療變得越來越普遍。

夥伴關係與合作關係：

製藥公司、學術機構和醫療機構共同合作推動藥物開發和商業化措施將加速市場發展。此次合作將促進資訊共享、資源共享和技術互補，進而提高腫瘤藥物在市場上的競爭力。

限制全球抗癌藥物市場的因素

有幾個因素可能會對抗腫瘤藥物市場造成市場限製或課題。這些包括：

嚴格的法律：

嚴格的立法：管理腫瘤藥物行銷和批准的嚴格立法可能會導致製造商推出新產品的時間延遲和成本增加。

開發成本高：

開發新型抗癌藥物需要大量的研究和開發，而且成本很高。此外，臨床試驗的失敗率進一步增加了製藥公司的成本。

專利已過期：

當主要腫瘤藥物的專利到期後，仿製藥可能會進入市場，從而壓低價格並減少品牌藥廠商的市場佔有率。

副作用：

抗腫瘤藥物雖然有效，但常產生噁心、嘔吐、掉髮、免疫抑制等嚴重副作用。對這些副作用的擔憂可能會限制醫生的處方率和患者的依從性。

抗藥性發展：

隨著時間的推移，腫瘤細胞可能會對抗癌藥物產生抗藥性，從而降低目前療法的有效性並需要開發新的治療方法。

限制獲得醫療保健的機會：

在某些地區，特別是發展中國家，由於缺乏醫療設施和治療費用過高，患者獲得抗癌藥物的機會可能會受到限制。

技術難題：

開發安全性和療效較佳的新型抗癌藥物在技術上極具課題性，需要大量的研發成本。

與替代療法競爭：

免疫療法和標靶療法是癌症治療中兩種越來越受歡迎的替代療法。傳統抗腫瘤藥物可能面臨這些替代療法的競爭，因為它們的療效和可用性不斷提高。

目錄

第 1 章全球腫瘤藥物市場：簡介

市場概況
• 研究範圍
• 先決條件

第 2 章執行摘要

第 3 章：經過驗證的市場研究方法

• 資料探勘
• 驗證
• 主要來源
• 資料來源列表

第四章 抗癌藥物全球市場展望

• 概述
• 市場動態
• 驅動程式
• 阻礙因素
• 機會
• 波特五力模型
• 價值鏈分析

5. 全球抗腫瘤藥物市場（依產品劃分）

• 概述
• 化療藥物
• 生物/免疫治療劑
• 個人化醫療

6. 全球抗腫瘤藥物市場（依應用）

• 概述
• 醫院
• 診所
• 癌症復健中心
• 門診手術中心

7. 全球抗腫瘤藥物市場（按地區）

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 德國
• 英國
• 法國
• 其他歐洲國家 亞太地區
• 中國
• 日本
• 印度
• 其他亞太地區
• 世界其他地區
• 拉丁美洲
• 中東和非洲

第 8 章。

• 概述
• 各公司的市場排名
• 主要發展策略

第九章 公司簡介

• Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb Company
• Baxter
• Boehringer Ingelheim
• Bayer
• Teva pharmaceutical Industries
• Johnson & Johnson
• Merck
• Pfize
• Accord Healthcare
• Lundbeck
• AbbVie

第 10 章附錄

• 相關報告

Anti-Neoplastic Agents Market Size And Forecast

Anti-Neoplastic Agents Market size was valued at USD 125.71 Billion in 2023 and is projected to reach USD 285.49 Billion by 2030 , growing at a CAGR of 7.1% during the forecasted period 2024 to 2030.

Global Anti-Neoplastic Agents Market Drivers

The market drivers for the Anti-Neoplastic Agents Market can be influenced by various factors. These may include:

Growing Cancer Incidence:

The market for anti-neoplastic agents is significantly influenced by the rising incidence of cancer worldwide. The need for efficient cancer treatments, such as anti-neoplastic drugs, is increasing as cancer rates rise as a result of ageing populations, changing lifestyles, and environmental factors.

Progress in Cancer Research:

The market for anti-neoplastic drugs is expanding due to ongoing efforts to better understand the molecular causes of cancer and to develop tailored treatments. Compared to conventional chemotherapy, targeted therapies provide more focused treatment options with fewer side effects, which has improved usage and expanded the market.

Technological Advancements:

The safety and effectiveness of anti-neoplastic drugs are improved by advances in drug delivery systems, including as liposomes, nanoparticles, and tailored drug delivery platforms. Through bettering patient experiences and treatment outcomes, these technology developments support market expansion.

Growing Healthcare Expenditure:

The adoption of cutting-edge cancer treatments, such as anti-neoplastic drugs, is supported by rising healthcare spending, especially in developing nations. Increased patient knowledge, insurance coverage expansions, and government initiatives all help to make these treatments more accessible.

Pipeline Development:

The market's expansion is fueled by a strong pipeline of innovative anti-neoplastic drugs that target different types of cancer. The variety of therapeutic alternatives is constantly being increased by pharmaceutical corporations and academic institutions through the development and testing of novel substances and treatment regimens.

Improved Treatment Outcomes:

Targeted anti-neoplastic drugs are in high demand due to the trend towards personalized medicine, in which patient features such as genetic makeup and tumor biomarkers are taken into account when designing a treatment plan. The market is expanding because personalized techniques result in better treatment outcomes and fewer side effects.

Regulatory Support:

Market access for anti-neoplastic drugs is facilitated by regulatory programmes that aim to accelerate drug development. Examples of these initiatives include faster approval processes and incentives for orphan drug classification. Promising regulatory frameworks facilitate the expeditious commercialization of novel medicines, hence propelling market expansion.

Global Ageing Population:

The need for anti-neoplastic medications is driven by the ageing population, especially in industrialized nations where it is a contributing factor to the rising incidence of cancer. Due to their increased cancer risk, older persons are driving up treatment costs and expanding the market.

Emerging Economies:

The market for anti-neoplastic drugs has enormous room to grow in emerging economies in Latin America, Africa, and Asia-Pacific. Advanced cancer treatments are more widely accessible in these areas due to factors like rising disposable incomes, rapid urbanization, and improved healthcare infrastructure.

Partnerships and Collaborations:

Pharmaceutical corporations, academic institutions, and healthcare organizations work together to expedite medication development and commercialization initiatives, which in turn spurs market expansion. Partnerships increase the competitiveness of anti-neoplastic agents in the market by facilitating information sharing, resource sharing, and access to complementary technologies.

Global Anti-Neoplastic Agents Market Restraints

Several factors can act as restraints or challenges for the Anti-Neoplastic Agents Market. These may include:

Strict laws:

Manufacturers may have difficulties as a result of the strict laws governing the marketing and approval of anti-neoplastic drugs, which could cause delays in the launch of new products and higher expenses.

High Development Costs:

Developing novel anti-neoplastic drugs requires a significant amount of research and development, which can be expensive. Furthermore, the cost burden on pharmaceutical businesses is further increased by the failure rate in clinical trials.

Patent Expiration:

When major anti-neoplastic medications' patents expire, generic competitors might join the market, driving down prices and eroding market share for the original producers.

Side Effects:

Anti-neoplastic drugs, although effective, frequently have serious side effects such as nausea, vomiting, hair loss, and immunosuppression. Physician prescription rates and patient compliance may be restricted due to worries about these negative effects.

Resistance Development:

Over time, tumor cells may become resistant to anti-neoplastic drugs, which will decrease the efficacy of current therapies and call for the creation of new ones.

Limited Access to Healthcare:

In certain areas, especially in developing nations, patients' access to anti-neoplastic drugs may be restricted by a lack of access to healthcare facilities and excessive treatment expenses.

Technological Difficulties:

Creating novel anti-neoplastic drugs with enhanced safety and efficacy profiles presents technological difficulties that call for hefty expenditures in R&D.

Competition from Alternative Therapies:

Immunotherapy and targeted therapy are two alternative therapies that are becoming more and more popular in the treatment of cancer. Traditional anti-neoplastic drugs may face competition from these alternatives due of their growing efficacy and availability.

Global Anti-Neoplastic Agents Market Segmentation Analysis

The Global Anti-Neoplastic Agents Market is segmented on the basis of Product, Application, And Geography.

Anti-Neoplastic Agents Market, By Product

• Chemotherapeutic Agents
• Biological/Immunotherapeutic Agents
• Personalized Medicine

Based on the Product, the market is bifurcated into Chemotherapeutic Agents Biological/Immunotherapeutic Agents and Personalized Medicine. Chemotherapeutic agents are predicted to hold the largest market share due to the ease of availability of drugs. Immunotherapeutic agents will grow with the highest CAGR owing to the growing acceptance of biological therapy as they have lesser side effects.

Anti-Neoplastic Agents Market, By Application

• Hospitals
• Clinics
• Cancer Rehabilitation Centers
• Ambulatory Surgical Centers

Based on the Application, the market is bifurcated into Hospitals, Clinics, Cancer Rehabilitation Centers, and Ambulatory Surgical Centers. Hospitals are anticipated to hold the maximum share as there is a vast number of cancer patients hospitalized in the hospitals every year. As per the statistics given by The Healthcare Cost and Utilization Project (H-cup), there were 4.7 Mn hospitalizations related to cancer in the U.S. in the year 2009 and about 6% of adult inpatient hospital cost was generated by the hospitalization of cancer patients.

Anti-Neoplastic Agents Market, By Geography

• North America
• Europe
• The Asia Pacific
• Rest of the world
• On the basis of Regional Analysis, the Global Anti-Neoplastic Agents Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America will continue to dominate the global Anti-Neoplastic Agents Market due to the high prevalence of malignant neoplasm. Europe is expected to hold the second-largest market share in the global Anti-Neoplastic Agents Market. In 2013, as per Cancer Research UK, 605 people per 100,000 general population were diagnosed with cancer.

Key Players

• Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb Company
• Baxter
• Boehringer Ingelheim
• Bayer
• Teva Pharmaceutical Industries
• Johnson & Johnson
• Merck
• Pfizer
• Accord Healthcare
• Lundbeck
• AbbVie

TABLE OF CONTENTS

1. Introduction of Global Anti-Neoplastic Agents Market

• Overview of the Market
• Scope of Report
• Assumptions

2. Executive Summary

3. Research Methodology of Verified Market Research

• Data Mining
• Validation
• Primary Interviews
• List of Data Sources

4. Global Anti-Neoplastic Agents Market Outlook

• Overview
• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Porters Five Force Model
• Value Chain Analysis

5. Global Anti-Neoplastic Agents Market, By Product

• Overview
• Chemotherapeutic Agents
• Biological/Immunotherapeutic Agents
• Personalized Medicine

6. Global Anti-Neoplastic Agents Market, By Application

• Overview
• Hospitals
• Clinics
• Cancer Rehabilitation Centers
• Ambulatory Surgical Centers

7. Global Anti-Neoplastic Agents Market, By Geography

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• Rest of the World
• Latin America
• Middle East & Africa

8. Global Anti-Neoplastic Agents Market Competitive Landscape

• Overview
• Company Market Ranking
• Key Development Strategies

9. Company Profiles

• Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb Company
• Baxter
• Boehringer Ingelheim
• Bayer
• Teva pharmaceutical Industries
• Johnson & Johnson
• Merck
• Pfize
• Accord Healthcare
• Lundbeck
• AbbVie

10. Appendix

• Related Reports